D
David J. Adelstein
Researcher at Cleveland Clinic
Publications - 270
Citations - 14672
David J. Adelstein is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Chemoradiotherapy & Head and neck cancer. The author has an hindex of 57, co-authored 263 publications receiving 12756 citations. Previous affiliations of David J. Adelstein include University of Michigan & University of Virginia.
Papers
More filters
Journal ArticleDOI
An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck Cancer
David J. Adelstein,Yi Li,George L. Adams,Henry N. Wagner,Julie A. Kish,John F. Ensley,David E. Schuller,Arlene A. Forastiere +7 more
TL;DR: The addition of concurrent high-dose, single-agent cisplatin to conventional single daily fractionated radiation significantly improves survival, although it also increases toxicity.
Journal ArticleDOI
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma
Thomas P. Miller,Steve Dahlberg,J. Robert Cassady,David J. Adelstein,Catherine M. Spier,Thomas M. Grogan,Michael LeBlanc,Susan Carlin,Ellen M. Chase,Richard I. Fisher +9 more
TL;DR: Three cycles of CHOP followed by involved-field radiotherapy are superior to eight cycles ofCHOP alone for the treatment of localized intermediate- and high-grade non-Hodgkin's lymphoma.
Journal ArticleDOI
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
Maura L. Gillison,Andy Trotti,Jonathan Harris,Avraham Eisbruch,Paul M. Harari,David J. Adelstein,Richard C.K. Jordan,Weiqiang Zhao,Erich M. Sturgis,Barbara Burtness,John A. Ridge,Jolie Ringash,James M. Galvin,Min Yao,Shlomo A. Koyfman,Dukagjin Blakaj,Mohammed A. Razaq,A. Dimitrios Colevas,Jonathan J. Beitler,Christopher U. Jones,Neal Dunlap,Samantha A. Seaward,Sharon A. Spencer,Thomas J. Galloway,Jack Phan,James J. Dignam,James J. Dignam,Quynh-Thu Le +27 more
TL;DR: After median follow-up duration of 4·5 years, radiotherapy plus cetuximab did not meet the non-inferiority criteria for overall survival, and patients were stratified by T category (T1-T2 vs T3-T4), N category (N0-N2a vs N2b-N3), Zubrod performance status (0 vs 1), and tobacco smoking history (≤10 pack-years).
Journal ArticleDOI
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
David G. Pfister,Sharon A. Spencer,David J. Adelstein,Douglas Adkins,Yoshimi Anzai,David M. Brizel,Justine Yang Bruce,Paul M. Busse,Jimmy J. Caudell,Anthony J. Cmelak,A. Dimitrios Colevas,David W. Eisele,Moon Fenton,Robert L. Foote,Thomas J. Galloway,Maura L. Gillison,Robert I. Haddad,Wesley L. Hicks,Ying J. Hitchcock,Antonio Jimeno,Debra S. Leizman,Ellie Maghami,Loren K. Mell,Bharat B. Mittal,Harlan A. Pinto,John A. Ridge,James W. Rocco,Cristina P. Rodriguez,Jatin P. Shah,Randal S. Weber,Gregory S. Weinstein,Matthew E. Witek,Frank Worden,Sue S. Yom,Weining Zhen,Jennifer L. Burns,Susan Darlow +36 more
TL;DR: The NCCN Guidelines for Head and Neck Cancers as mentioned in this paper describe supportive care recommendations for patients with H&N cancers and the rationale supporting a new section on imaging recommendations for head and neck cancers.
Journal ArticleDOI
Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study
Brian O'Sullivan,Shao Hui Huang,Jie Su,Adam S. Garden,Erich M. Sturgis,Kristina R. Dahlstrom,Nancy Y. Lee,Nadeem Riaz,Xin Pei,Shlomo A. Koyfman,David J. Adelstein,Brian B. Burkey,Jeppe Friborg,Claus A. Kristensen,Anita Gothelf,Frank J. P. Hoebers,Bernd Kremer,Ernst-Jan M. Speel,Daniel W. Bowles,David Raben,Sana D. Karam,Eugene Yu,Wei Xu +22 more
TL;DR: Overall survival at 5 years between training and validation cohorts according to 7th edition TNM classifications and HPV status was similar, and AHR-New was selected as the proposed ICON-S stage classification.